Ann Intern Med

1. LALANI HS, DiResta R, Baron RJ, Scales D, et al
   Addressing Viral Medical Rumors and False or Misleading Information.
   Ann Intern Med. 2023 Jul 18. doi: 10.7326/M23-1218.
   

   >> Share

   
   

   
   Antimicrob Agents Chemother

2. ZHENG X, You X, Liu Y, Wu B, et al
   Spatiotemporal dynamics and multiple driving factors of antimicrobial resistance in China during the COVID-19 pandemic (2019-2023): a provincial panel data analysis.
   Antimicrob Agents Chemother. 2026 Feb 9:e0160025. doi: 10.1128/aac.01600.
   

   >> Share

   
   

   
   Antiviral Res

3. ZHANG T, Wang ZL, Li XY, Luo RH, et al
   Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
   Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
   

   >> Share

   
   
4. YURGELONIS I, Rai DK, Li Z, Washington B, et al
   Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
   Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
   

   >> Share

   
   
5. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
   Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
   Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

6. DEO S, Desai K, Patare A, Wadapurkar R, et al
   Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies.
   Biochem Biophys Res Commun. 2023;680:108-118.
   

   >> Share

   
   

   
   Cell

7. YU S, Lin Y, Li Y, Chen S, et al
   Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine.
   Cell. 2023;186:4615-4631.
   

   >> Share

   
   

   
   Epidemiol Infect

8. FUNG IC, Liang H, Pierce KJ, Kraay ANM, et al
   Excess mortality in Mainland China after the end of the Zero COVID policy: A systematic review.
   Epidemiol Infect. 2026;154:e29.
   

   >> Share

   
   
9. AKBARIAN S, Sheikhi M, Khedri P, Baharifar N, et al
   The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients.
   Epidemiol Infect. 2023;151:e158.
   

   >> Share

   
   

   
   Eur J Epidemiol

10. SLURINK IAL, de Boer AR, Bonten MJM, Sturkenboom MCJM, et al
    COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands.
    Eur J Epidemiol. 2026;41:173-184.
    

    >> Share

    
    

    
    J Epidemiol Community Health

11. BEVILACQUA L, Fox-Smith L, Lewins A, Jetha P, et al
    Impact of COVID-19 on the mental health of children and young people: an umbrella review.
    J Epidemiol Community Health. 2023;77:704-709.
    

    >> Share

    
    

    
    J Gen Virol

12. NAZKI S, Tennakoon C, Reddy VRAP, Chen Y, et al
    Evaluating how infectious bursal disease virus (IBDV) infection influences influenza H3N8 challenge in chickens.
    J Gen Virol. 2026;107:002235.
    

    >> Share

    
    
13. DISLERS A, Nilova O, Jansons J, Skrastina D, et al
    Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
    J Gen Virol. 2026;107:002240.
    

    >> Share

    
    

    
    J Infect

14. ZHOU T, Zhang B, Zhang D, Jhaveri R, et al
    Pre-COVID-19 Body Mass Index and Postacute Cardiovascular, Gastrointestinal, and Neuropsychiatric Outcomes Among Children and Young Adults With SARS-CoV-2 Infection: An EHR-based Cohort Study from the RECOVER Initiative.
    J Infect. 2026 Feb 11:106702. doi: 10.1016/j.jinf.2026.106702.
    

    >> Share

    
    
15. WANG Z, Dunican C, Dayananda P, Ingar S, et al
    Comparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease.
    J Infect. 2026;92:106696.
    

    >> Share

    
    

    
    J Virol

16. FIELD CJ, Septer KM, Patel DR, Weaver VC, et al
    Defining the transmissible dose 50% for two pandemic influenza viruses in ferrets.
    J Virol. 2026 Mar 11:e0163525. doi: 10.1128/jvi.01635.
    

    >> Share

    
    
17. HAN P, Meng Y, Zhang D, Xu Z, et al
    Structural basis of white-tailed deer, Odocoileus virginianus, ACE2 recognizing all the SARS-CoV-2 variants of concern with high affinity.
    J Virol. 2023 Sep 7:e0050523. doi: 10.1128/jvi.00505.
    

    >> Share

    
    

    
    JAMA

18. WANG L, Nangle SJ, Waller-Pulido A, McMahan K, et al
    Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.
    JAMA. 2026 Mar 9:e262173. doi: 10.1001/jama.2026.2173.
    

    >> Share

    
    
19. JABAGI MJ, Bertrand M, Gabet A, Kolla E, et al
    Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
    JAMA. 2025 Dec 22:e2524082. doi: 10.1001/jama.2025.24082.
    

    >> Share

    
    

    
    Lancet

20. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

21. MALONEY P, Reeves EL, Wielgosz K, Price AM, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:116-123.
    

    >> Share

    
    
22. ZHU S, Quint J, Leon TM, Li NJ, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:124-128.
    

    >> Share

    
    

    
    N Engl J Med

23. 
    Current and Emerging Approaches to Evaluating Influenza Vaccine Performance.
    N Engl J Med. 2026;394:1144.
    

    >> Share

    
    

    
    Pediatrics

24. YAN AP, Archer NM, Arnold D, Hansbury E, et al
    Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.
    Pediatrics. 2023;152:e2022061011.
    

    >> Share

    
    

    
    PLoS Comput Biol

25. LOPES R, Lan Y, Chitwood MH, Klaassen F, et al
    Quantifying the spatiotemporal dynamics of the first two epidemic waves of SARS-CoV-2 infections in the United States.
    PLoS Comput Biol. 2026;22:e1013983.
    

    >> Share

    
    

    
    PLoS Med

26. KAMPITSI CE, Louro J, Mogensen H, Erdmann F, et al
    Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study.
    PLoS Med. 2026;23:e1004934.
    

    >> Share

    
    

    
    PLoS One

27. ALI MA, Sheikh H, Reza MS, Paul TR, et al
    Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.
    PLoS One. 2026;21:e0337970.
    

    >> Share

    
    
28. CASTILLO-NAVARRETE JL, Bustos C, Guzman-Castillo A, Munoz-Reveco L, et al
    Development and validation of the BASE-66 inventory for comprehensive academic stress measurement.
    PLoS One. 2026;21:e0343308.
    

    >> Share

    
    
29. SOGBESAN A, Bakare AA, Herzig van Wees S, Salako J, et al
    Exploring COVID-19 pandemic perceptions and vaccine uptake among community members and primary healthcare workers in Nigeria: A mixed methods study.
    PLoS One. 2026;21:e0310437.
    

    >> Share

    
    
30. MESQUITA LO, Dos Santos DF, de Carvalho KMB
    Effect of COVID-19 on mortality due to diabetes mellitus in Brazil: A time series analysis from 2010 to 2023.
    PLoS One. 2026;21:e0344419.
    

    >> Share

    
    
31. NELSON CE, Kauffman KD, Sakai S, Newbolt T, et al
    Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.
    PLoS One. 2026;21:e0342849.
    

    >> Share

    
    
32. DHOUIB W, Kacem M, Belghayeb O, Beji MO, et al
    Serological profile of naive patients affected by the first sars-cov-2 variant: A prospective study.
    PLoS One. 2026;21:e0344308.
    

    >> Share

    
    
33. DUAH ASUMADU OK, Abiiro GA, Ndago JA, Kanligi DA, et al
    Prevalence and associated factors of health facility delivery during COVID-19 in the Tamale Metropolis of Ghana: Analytical cross-sectional study.
    PLoS One. 2026;21:e0344205.
    

    >> Share

    
    
34. HU YZ, Qin ZL, Tang W, Hu ZL, et al
    Influence of COVID-19 on postoperative prognosis and pain management.
    PLoS One. 2026;21:e0344211.
    

    >> Share

    
    
35. ANTUNES L, Nunes B, Nunez O, Martinez-Baz I, et al
    Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.
    PLoS One. 2026;21:e0343988.
    

    >> Share

    
    
36. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
    Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
    PLoS One. 2026;21:e0342984.
    

    >> Share

    
    
37. BAEK S, Cho H, Lee S, Yoo M, et al
    Integrated disease model considering mutation-induced infection waves with COVID-19 cases.
    PLoS One. 2026;21:e0341667.
    

    >> Share

    
    
38. SULIMANY HGH, Almoataz E, Ali A, Faisal F, et al
    Moderating role of CEO expertise on the relationship between capital structure and financial reporting timeliness of Saudi-listed companies.
    PLoS One. 2026;21:e0338840.
    

    >> Share

    
    
39. MAGALHAES JCN, Chiavegatto Filho ADP
    Predictive divergence in machine learning models for clinical mortality risk: A multicohort study of covid-19 patients.
    PLoS One. 2026;21:e0344354.
    

    >> Share

    
    
40. BHANDARI B, Thapa P, Timilsina A, Karn RR, et al
    "It becomes more difficult when people don't empathize with us": COVID-19-related stigmatization experienced by survivors in Nepal.
    PLoS One. 2026;21:e0344123.
    

    >> Share

    
    
41. ATAC O, Aydin V, Peterson LE, Waters TM, et al
    The impact of the COVID-19 pandemic on oral anticoagulation adherence in patients with atrial fibrillation managed in primary care: Results from the PRIME Registry.
    PLoS One. 2026;21:e0344020.
    

    >> Share

    
    
42. BARTMANN C, Schmidt V, Morz M, Schwab M, et al
    Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women.
    PLoS One. 2026;21:e0344185.
    

    >> Share

    
    
43. CORONADO ZK, Duke M, Rodriguez M, Avelar Portillo LJ, et al
    Latino/a experiences of homelessness in California: Qualitative findings from the California Statewide Study of People Experiencing Homelessness (CASPEH).
    PLoS One. 2026;21:e0344036.
    

    >> Share

    
    
44. HAMROUNI M, Gupta A, Middleton S, Prosper S, et al
    The Nottingham recovery from COVID-19 research platform (NoRCoRP): Functional, clinical and patient-reported outcomes in adults referred to a post-COVID respiratory service.
    PLoS One. 2026;21:e0344210.
    

    >> Share

    
    
45. WU C, Paradis NJ
    Near Neutral Selectionist Theories (NNST) for SARS-CoV-2 suggested by the substitution-mutation ratio (c/micro) analysis.
    PLoS One. 2026;21:e0343410.
    

    >> Share

    
    
46. DIMNJAKOVIC J, Buble T, Poljicanin T, Brborovic H, et al
    Identifying high-risk combinations of metformin during COVID-19.
    PLoS One. 2026;21:e0343979.
    

    >> Share

    
    
47. KIM TY, Min GJ, Cho SG, Kim S, et al
    Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
    PLoS One. 2026;21:e0328666.
    

    >> Share

    
    
48. RICHARD L, Carter B, Liu M, Nisenbaum R, et al
    Acute healthcare utilization associated with positive SARS-CoV-2 testing or serology among people experiencing homelessness: A prospective cohort study.
    PLoS One. 2026;21:e0343639.
    

    >> Share

    
    
49. KASULE J, Tonzel JL, Burns N, Hamby T, et al
    COVID-19 knowledge, attitudes, and practices among people vulnerable to HIV in Uganda: A cross-sectional cohort analysis.
    PLoS One. 2026;21:e0343507.
    

    >> Share

    
    
50. ALOMARI HM, Bani Hani H, Alkhateeb T, Qutaishat D, et al
    Adoption and implementation of teleaudiology as a telehealth model in Jordan and Arab countries: A cross-sectional survey.
    PLoS One. 2026;21:e0343923.
    

    >> Share

    
    
51. FROLKE SC, Amirkhan KG, van der Bom-Baylon N, van Gils M, et al
    Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.
    PLoS One. 2026;21:e0336320.
    

    >> Share

    
    
52. CASSIM N, Coetzee LM, da Silva MP, Stevens WS, et al
    Using laboratory data to assess the impact of coronavirus (COVID-19) on reflex cryptococcal antigenaemia (CrAg) testing in South Africa.
    PLoS One. 2023;18:e0292062.
    

    >> Share

    
    
53. STONEHAM CA, Singh R, De Leon A, Tafelmeyer P, et al
    A cluster of acidic residues in the cytoplasmic domain of SARS-CoV-2 Spike is required for virion-incorporation and infectivity.
    PLoS One. 2026;21:e0340644.
    

    >> Share

    
    
54. MAZHAR L, Krebs N, Allen SI, Hobkirk AL, et al
    Enhancing recruitment and retention strategies in human tobacco research.
    PLoS One. 2026;21:e0340668.
    

    >> Share

    
    
55. LAU HC, Sekawi Z, Ching SM, Abu Bakar N, et al
    Effectiveness of the influenza and Tdap vaccination educational module (InTroDuce-Programme) on knowledge and intention for antenatal vaccination: A cluster randomised controlled trial protocol among pregnant women in Malaysian primary care clinics.
    PLoS One. 2026;21:e0344651.
    

    >> Share

    
    
56. PAN Y, Fan L, Goetz S
    Economic shocks, food insufficiency and mental health: Evidence from the COVID-19 pandemic.
    PLoS One. 2026;21:e0344745.
    

    >> Share

    
    
57. JONES M, Reilly M, Simanek A, Stewart A, et al
    A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes.
    PLoS One. 2026;21:e0344258.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

58. ESPINOZA B, Venkatramanan S, Scott Warren A, Lewis BL, et al
    Integrated framework to study genomic surveillance of selective sweeps in multivariants dynamics.
    Proc Natl Acad Sci U S A. 2026;123:e2521031123.
    

    >> Share

    
    
59. FARAONE JN, Li P, Hong J, Zang J, et al
    Spike destabilization attenuates Mink Cluster 5 SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2528367123.
    

    >> Share

    
    

    
    Vaccine

60. MESLE MMI, Jorgensen P, Barakat A, Herring BL, et al
    Influenza vaccine recommendations and coverage (2018-2023): a foundation for pandemic preparedness and response.
    Vaccine. 2026;78:128391.
    

    >> Share

    
    
61. MALLAH N, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, et al
    Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
    Vaccine. 2026;79:128435.
    

    >> Share

    
    
62. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023;41:6488-6501.
    

    >> Share

    
    
63. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023;41:6406-6410.
    

    >> Share

    
    
64. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023;41:6548-6557.
    

    >> Share

    
    
65. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023;41:6514-6528.
    

    >> Share

    
    
66. JACOBS ET, Cordova-Marks FM, Farland LV, Ernst KC, et al
    Understanding low COVID-19 booster uptake among US adults.
    Vaccine. 2023;41:6221-6226.
    

    >> Share

    
    
67. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023;41:6248-6254.
    

    >> Share

    
    
68. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023;41:6281-6290.
    

    >> Share

    
    
69. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023;41:6366-6378.
    

    >> Share

    
    
70. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023;41:6444-6452.
    

    >> Share

    
    
71. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023;41:6505-6513.
    

    >> Share

    
    
72. JALALIZADEH M, Leme PAF, Buosi K, Dionato FAV, et al
    Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guerin (BCG) in the BATTLE trial.
    Vaccine. 2023;41:6599-6606.
    

    >> Share

    
    

    
    Virology

73. ORTEGA GRANDA O, Alvarez K, Mate-Perez MJ, Canard B, et al
    Macro1 domain residue F156: A hallmark of SARS-CoV-2 de-MARylation specificity.
    Virology. 2023;587:109845.
    

    >> Share

    
    
74. HAKIM MS, Widyaningsih SA, Ikram A, Goeijenbier M, et al
    Fundamental concepts of convergent (parallel) evolution in human-pathogenic viruses and their implications for global health.
    Virology. 2026;618:110854.
    

    >> Share

    
    
75. KIM IH, No JS, Kim JA, Park AK, et al
    Genomic epidemiology of SARS-CoV-2 variants in South Korea between January 2020 and February 2023.
    Virology. 2023;587:109869.
    

    >> Share

    
    
76. KNANY HR, Elsabbagh SA, Shehata MA, Eldehna WM, et al
    In silico screening of SARS-CoV2 helicase using African natural products: Docking and molecular dynamics approaches.
    Virology. 2023;587:109863.
    

    >> Share

    
    
77. SHIAU AL, Lee KH, Cho HY, Chuang TH, et al
    Molnupiravir, a ribonucleoside antiviral prodrug against SARS-CoV-2, alters the voltage-gated sodium current and causes adverse events.
    Virology. 2023;587:109865.
    

    >> Share

    
    
78. PONDE RAA
    Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants.
    Virology. 2023;587:109850.
    

    >> Share

    
    

    
    Virus Res

79. BONIARDI I, Corona A, Basquin J, Basquin C, et al
    Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function.
    Virus Res. 2023;336:199221.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share